Iterum Therapeutics plc (NASDAQ:ITRM) Q1 2021 Earnings Conference Call May 14, 2021 8:30 AM ET Company Participants Louise Barrett - Senior Vice President of Legal Affairs Corey Fishman - Chief Executive Officer Judy Matthews - Chief Financial Officer Conference Call Participants Gregory Renza - RBC Capital Markets Ed Arce - H.C. Wainwright Kevin Kedra - G Research Operator Ladies and gentlemen, welcome to the Iterum Therapeutics First Quarter 2021 Financial Results Conference Call. My name is Katie and I' ...

ITherapeutics ERUM Company Overview April 2021 Oral and IV treatment for serious bacterial infections ERUM 1 ITherapeutics Forward-looking Statements & Disclaimer This presentation contains forward-looking statements. These forward-looking statements include, without limitation, statements regarding the development, therapeutic and market potential of sulopenem, the sufficiency of cash resources, the granting or issuing of patents, the expected timing of NDA and EMA filings and our plans, strategies and pro ...

Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2020 Results Conference Call March 12, 2021 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs Corey Fishman - CEO Judy Matthews - CFO Conference Call Participants Gregory Renza - RBC Capital Markets Ed Arce - H.C. Wainwright Kevin Kedra - Gabelli Research Louise Barrett Good morning everyone and welcome to Iterum Therapeutics Fourth Quarter and Full Year 2020 Financial Results and Corporate Update Conference Call. Our press release with the Company’ ...

ITherapeutics ERUM Company Overview February 2021 Oral and IV treatment for serious bacterial infections ERUM 1 ITherapeutics Forward-looking Statements & Disclaimer This presentation contains forward-looking statements. These forward-looking statements include, without limitation, statements regarding the development, therapeutic and market potential of sulopenem, the sufficiency of cash resources, the granting or issuing of patents, the expected timing of NDA and EMA filings and our plans, strategies and ...

ITherapeutics ERUM Company Overview April, 2020 Oral and IV treatment for serious bacterial infections ERUM 1 ITherapeutics Forward-looking Statements & Disclaimer This presentation contains forward-looking statements. These forward-looking statements include, without limitation, statements regarding the development, therapeutic and market potential of sulopenem, the sufficiency of cash resources, the granting or issuing of patents, the timing, progress and results of clinical trials, and the expected timin ...

ITherapeutics ERUM Company Overview October 2019 Oral and IV treatment for serious bacterial infections ERUM 1 CONFIDENTIAL ITherapeutics Forward-looking Statements & Disclaimer This presentation contains forward-looking statements. These forward-looking statements include, without limitation, statements regarding the development, therapeutic and market potential of sulopenem, the sufficiency of cash resources, the granting or issuing of patents, the timing, progress and results of clinical trials, and the ...

ITherapeutics ERUM Company Overview August 2019 Oral and IV treatment for serious bacterial infections ERUM 1 CONFIDENTIAL ITherapeutics Forward-looking Statements & Disclaimer This presentation contains forward-looking statements. These forward-looking statements include, without limitation, statements regarding the development, therapeutic and market potential of sulopenem, the sufficiency of cash resources, the granting or issuing of patents, the timing, progress and results of clinical trials, and the e ...